Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: To facilitate translational work in medications development for smoking cessation, we have developed a human laboratory analogue of smoking lapse behavior. Our paradigm models 2 critical features of smoking lapse: the ability to resist the first cigarette and subsequent ad libitum smoking. In this paper we present the results of 2 studies designed to develop and validate the effect of nicotine deprivation on smoking lapse behavior. METHODS: Study 1 (n = 30) was designed to develop the model parameters by examining varying levels of nicotine deprivation (1, 6, and 18 hr; within-subject) and identifying optimum levels of monetary reinforcement to provide while modeling the ability to resist smoking. Study 2 was designed to validate the model by screening smoking cessation medications with known clinical efficacy. Subjects (n = 62) were randomized to either varenicline 2 mg/day, bupropion 300 mg/day, or placebo, and we then modeled their ability to resist smoking and subsequent ad libitum smoking. RESULTS: In Study 1, increasing levels of nicotine deprivation and decreasing levels of monetary reinforcement decreased the ability to resist smoking. In Study 2, the lapse model was found to be sensitive to medication effects among smokers who demonstrated a pattern of heavy, uninterrupted, and automated smoking (i.e., smoked within 5 min of waking). Ratings of craving, mood, withdrawal, and subjective cigarette effects are presented as secondary outcomes with results mirroring clinical findings. CONCLUSIONS: Our smoking lapse model demonstrates promise as a translational tool to screen novel smoking cessation medications. Next steps in this line of research will focus on evaluating predictive validity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 3×
“One week of pretreatment for both bupropion and varenicline is the typical pretreatment period used in smoking cessation trials (prior to the quit day), as steady - state levels are achieved within this timeframe ( Jorenby et al., 1999 , 2006 ).”
BackgroundMethodA controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 2×
“One week of pretreatment for both bupropion and varenicline is the typical pretreatment period used in smoking cessation trials (prior to the quit day), as steady - state levels are achieved within this timeframe ( Jorenby et al., 1999 , 2006 ).”
MethodGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 1×
“To this end, we examined whether varenicline and bupropion ( Gonzales et al., 2006 ; Jorenby et al., 2006 ) increased the ability to resist smoking and reduced subsequent smoking.”
BackgroundCox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
First lapses to smoking: Within-subjects analysis of real-time reports.
Shiffman, S., Paty, J. A., Gnys, M., Kassel, J. A., & Hickcox, M. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.64.2.366 · Cited by 745
Stress decreases the ability to resist smoking and potentiates smoking intensity and reward
McKee, S. A., Sinha, R., Weinberger, A. H., Sofuoglu, M., Harrison, E. L., Lavery, M., & Wanzer, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110376694 · Cited by 276
Self-citationWest, R., Baker, C. L., Cappelleri, J. C., & Bushmakin, A. G. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1041-3 · Cited by 203
Bupropion for Smoking Cessation
Dale, L. C., Glover, E. D., Sachs, D. P. L., Schroeder, D. R., Offord, K. P., Croghan, I. T., & Hurt, R. D. (2001) · Chest · doi:10.1378/chest.119.5.1357 · Cited by 177
Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis
Nides, M. (2008) · American Journal of Health Behavior · doi:10.5993/ajhb.32.6.10 · Cited by 121
Developing human laboratory models of smoking lapse behavior for medication screening
McKee, S. A. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00135.x · Cited by 93 · cited 4×
“(see Harrison, Coppola, & McKee, 2009 for details and results).”
MethodSelf-citation
Cited by
An overview of alcohol and tobacco/nicotine interactions in the human laboratory
Verplaetse, T. L., & McKee, S. A. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1189927 · Cited by 160
Self-citationMcKee, S. A., Potenza, M. N., Kober, H., Sofuoglu, M., Arnsten, A. F., Picciotto, M. R., Weinberger, A. H., Ashare, R., & Sinha, R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114562091 · Cited by 75
“Using a validated human laboratory analogue of smokinglapse which targets the first instance of smoking during a quit attempt (McKee et al., 2012), we demonstrated that personalized stress imagery decreased the ability to resist smoking, and increased tobacco craving and subsequent cigarette…”
MethodResultSelf-citationThe effects of varenicline on stress-induced and cue-induced craving for cigarettes
Ray, L. A., Lunny, K., Bujarski, S., Moallem, N., Krull, J. L., & Miotto, K. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.015 · Cited by 27
Hamidovic, A., Khafaja, M., Brandon, V, Anderson, J., Ray, G., Allan, A. M., & Burge, M. R. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.234 · Cited by 24
Otto, M. W., Zvolensky, M. J., Rosenfield, D., Hoyt, D. L., Witkiewitz, K., McKee, S. A., Bickel, W. K., & Smits, J. A. J. (2020) · Health Psychology · doi:10.1037/hea0000858 · Cited by 12
Self-citation
Metadata
- Authors
- McKee, S. A., Weinberger, A. H., Shi, J., Tetrault, J., & Coppola, S.
- Venue
- Nicotine & Tobacco Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04-06
- Volume
- 14
- Issue
- 11
- Pages
- 1362-1371
- ISSN
- 1462-2203 (ISSN-L)
- 1469-994X
- OpenAlex
- W2029952168
- Cited by
- 83
- References
- 11
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.